Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to -$8000.0.

  • Seres Therapeutics' Cash from Investing Activities fell 10000.57% to -$8000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$313000.0, marking a year-over-year decrease of 10022.12%. This contributed to the annual value of $142.3 million for FY2024, which is 124467.02% up from last year.
  • Latest data reveals that Seres Therapeutics reported Cash from Investing Activities of -$8000.0 as of Q3 2025, which was down 10000.57% from -$181000.0 recorded in Q2 2025.
  • In the past 5 years, Seres Therapeutics' Cash from Investing Activities ranged from a high of $141.1 million in Q3 2024 and a low of -$20.7 million during Q1 2021
  • Its 5-year average for Cash from Investing Activities is $15.7 million, with a median of $2.7 million in 2023.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 31975.2% in 2021, then soared by 795436.84% in 2024.
  • Quarter analysis of 5 years shows Seres Therapeutics' Cash from Investing Activities stood at $13.2 million in 2021, then plummeted by 55.06% to $5.9 million in 2022, then plummeted by 114.8% to -$877000.0 in 2023, then soared by 89.74% to -$90000.0 in 2024, then surged by 91.11% to -$8000.0 in 2025.
  • Its Cash from Investing Activities stands at -$8000.0 for Q3 2025, versus -$181000.0 for Q2 2025 and -$34000.0 for Q1 2025.